share_log

When Will Evolus, Inc. (NASDAQ:EOLS) Breakeven?

When Will Evolus, Inc. (NASDAQ:EOLS) Breakeven?

Evolus, Inc. (纳斯达克:EOLS) 何时能实现盈亏平衡?
Simply Wall St ·  09/13 08:11

We feel now is a pretty good time to analyse Evolus, Inc.'s (NASDAQ:EOLS) business as it appears the company may be on the cusp of a considerable accomplishment. Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. With the latest financial year loss of US$62m and a trailing-twelve-month loss of US$53m, the US$963m market-cap company alleviated its loss by moving closer towards its target of breakeven. As path to profitability is the topic on Evolus' investors mind, we've decided to gauge market sentiment. We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.

我们认为现在是分析 Evolus, Inc. 的好时机。”s(纳斯达克股票代码:EOLS)的业务看来该公司可能正处于取得重大成就的风口浪尖。Evolus, Inc. 是一家高性能美容公司,专注于在美国、加拿大和欧洲的现金支付美学市场上提供产品。这家市值为9.63亿美元的公司最近一个财年的亏损为6200万美元,过去十二个月的亏损为5300万美元,通过接近盈亏平衡的目标来缓解亏损。由于盈利之路是Evolus投资者心目中的话题,我们决定评估市场情绪。我们简要概述了行业分析师对该公司、盈亏平衡年份和隐含增长率的预期。

According to the 6 industry analysts covering Evolus, the consensus is that breakeven is near. They anticipate the company to incur a final loss in 2025, before generating positive profits of US$37m in 2026. Therefore, the company is expected to breakeven roughly 2 years from now. In order to meet this breakeven date, we calculated the rate at which the company must grow year-on-year. It turns out an average annual growth rate of 69% is expected, which is rather optimistic! Should the business grow at a slower rate, it will become profitable at a later date than expected.

根据报道Evolus的6位行业分析师的说法,人们的共识是盈亏平衡已接近尾声。他们预计该公司将在2025年蒙受最终亏损,然后在2026年产生3700万美元的正利润。因此,预计该公司将在大约两年后实现盈亏平衡。为了达到这个盈亏平衡日期,我们计算了公司必须同比增长的速度。事实证明,预计年均增长率为69%,这是相当乐观的!如果业务增长速度放缓,则盈利的时间将比预期的晚。

big
NasdaqGM:EOLS Earnings Per Share Growth September 13th 2024
纳斯达克通用汽车:EOLS 每股收益增长 2024 年 9 月 13 日

Given this is a high-level overview, we won't go into details of Evolus' upcoming projects, but, bear in mind that generally pharmaceuticals, depending on the stage of product development, have irregular periods of cash flow. So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.

鉴于这是一个高层次的概述,我们不会详细介绍Evolus即将推出的项目,但请记住,通常药品的现金流,视产品开发阶段而定,会有不规则的现金流。因此,高增长率并非不寻常,尤其是在公司处于投资期时。

One thing we would like to bring into light with Evolus is its debt-to-equity ratio of over 2x. Generally, the rule of thumb is debt shouldn't exceed 40% of your equity, and the company has considerably exceeded this. A higher level of debt requires more stringent capital management which increases the risk in investing in the loss-making company.

我们想通过Evolus揭示的一件事是其债务与权益比率超过2倍。通常,经验法则是债务不应超过您权益的40%,而公司已经大大超过了这一水平。更高的债务水平需要更严格的资本管理,这增加了投资这家亏损公司的风险。

Next Steps:

后续步骤:

There are key fundamentals of Evolus which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at Evolus, take a look at Evolus' company page on Simply Wall St. We've also put together a list of essential factors you should further examine:

本文未涵盖Evolus的关键基础知识,但我们必须再次强调,这只是一个基本的概述。要更全面地了解 Evolus,请查看 Simply Wall St 上的 Evolus 公司页面。我们还整理了一份你应该进一步研究的基本因素清单:

  1. Valuation: What is Evolus worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Evolus is currently mispriced by the market.
  2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Evolus's board and the CEO's background.
  3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
  1. 估值:Evolus 今天的价值是多少?价格中是否已经考虑了未来的增长潜力?我们的免费研究报告中的内在价值信息图有助于可视化Evolus目前是否被市场错误定价。
  2. 管理团队:由经验丰富的管理团队掌舵增强了我们对业务的信心——看看谁是Evolus董事会成员以及首席执行官的背景。
  3. 其他表现优异的股票:还有其他股票可以提供更好的前景并有良好的往绩记录吗?在这里浏览我们免费列出的这些优质股票。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧吗?请直接联系我们。或者,也可以发送电子邮件至编辑团队 (at) simplywallst.com。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发